Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol

Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tia L. Kauffman, Yolanda K. Prado, Ana A. Reyes, Jamilyn M. Zepp, Jennifer Sawyer, Larissa Lee White, Jessica Martucci, Suzanne Bianca Salas, Sarah Vertrees, Alan F. Rope, Sheila Weinmann, Nora B. Henrikson, Sandra Soo-Jin Lee, Heather Spencer Feigelson, Jessica Ezzell Hunter
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ovarian cancer traceback testing cascade testing post-mortem genetic testing pathology hereditary breast Medicine R
Acceso en línea:	https://doaj.org/article/dd6940c5a01a418ead4edf9bdb1cd92c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dd6940c5a01a418ead4edf9bdb1cd92c
record_format	dspace
spelling	oai:doaj.org-article:dd6940c5a01a418ead4edf9bdb1cd92c2021-11-25T18:07:55ZFeasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol10.3390/jpm111111942075-4426https://doaj.org/article/dd6940c5a01a418ead4edf9bdb1cd92c2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1194https://doaj.org/toc/2075-4426Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer variants. For deceased individuals, post-mortem genetic testing of pathology specimens allows surviving family members to receive important genetic risk information. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. This study will assess the potential ethical and privacy concerns related to an ovarian cancer traceback testing approach in the context of patients who are deceased, followed by implementation and evaluation of the feasibility of an ovarian cancer traceback testing approach using tumor registries and archived pathology tissue. Descriptive and statistical analyses will assess health system and patient characteristics associated with the availability of pathology tissue and compare the ability to contact and uptake of genetic testing between patients who are living and deceased. The results of this study will inform the implementation of future traceback programs.Tia L. KauffmanYolanda K. PradoAna A. ReyesJamilyn M. ZeppJennifer SawyerLarissa Lee WhiteJessica MartucciSuzanne Bianca SalasSarah VertreesAlan F. RopeSheila WeinmannNora B. HenriksonSandra Soo-Jin LeeHeather Spencer FeigelsonJessica Ezzell HunterMDPI AGarticleovarian cancertraceback testingcascade testingpost-mortem genetic testingpathologyhereditary breastMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1194, p 1194 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ovarian cancer traceback testing cascade testing post-mortem genetic testing pathology hereditary breast Medicine R
spellingShingle	ovarian cancer traceback testing cascade testing post-mortem genetic testing pathology hereditary breast Medicine R Tia L. Kauffman Yolanda K. Prado Ana A. Reyes Jamilyn M. Zepp Jennifer Sawyer Larissa Lee White Jessica Martucci Suzanne Bianca Salas Sarah Vertrees Alan F. Rope Sheila Weinmann Nora B. Henrikson Sandra Soo-Jin Lee Heather Spencer Feigelson Jessica Ezzell Hunter Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
description	Guidelines currently state that genetic testing is clinically indicated for all individuals diagnosed with ovarian cancer. Individuals with a prior diagnosis of ovarian cancer who have not received genetic testing represent missed opportunities to identify individuals with inherited high-risk cancer variants. For deceased individuals, post-mortem genetic testing of pathology specimens allows surviving family members to receive important genetic risk information. The Genetic Risk Assessment in Ovarian Cancer (GRACE) study aims to address this significant healthcare gap using a “traceback testing” approach to identify individuals with a prior diagnosis of ovarian cancer and offer genetic risk information to them and their family members. This study will assess the potential ethical and privacy concerns related to an ovarian cancer traceback testing approach in the context of patients who are deceased, followed by implementation and evaluation of the feasibility of an ovarian cancer traceback testing approach using tumor registries and archived pathology tissue. Descriptive and statistical analyses will assess health system and patient characteristics associated with the availability of pathology tissue and compare the ability to contact and uptake of genetic testing between patients who are living and deceased. The results of this study will inform the implementation of future traceback programs.
format	article
author	Tia L. Kauffman Yolanda K. Prado Ana A. Reyes Jamilyn M. Zepp Jennifer Sawyer Larissa Lee White Jessica Martucci Suzanne Bianca Salas Sarah Vertrees Alan F. Rope Sheila Weinmann Nora B. Henrikson Sandra Soo-Jin Lee Heather Spencer Feigelson Jessica Ezzell Hunter
author_facet	Tia L. Kauffman Yolanda K. Prado Ana A. Reyes Jamilyn M. Zepp Jennifer Sawyer Larissa Lee White Jessica Martucci Suzanne Bianca Salas Sarah Vertrees Alan F. Rope Sheila Weinmann Nora B. Henrikson Sandra Soo-Jin Lee Heather Spencer Feigelson Jessica Ezzell Hunter
author_sort	Tia L. Kauffman
title	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_short	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_full	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_fullStr	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_full_unstemmed	Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol
title_sort	feasibility of a traceback approach for using pathology specimens to facilitate genetic testing in the genetic risk analysis in ovarian cancer (grace) study protocol
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/dd6940c5a01a418ead4edf9bdb1cd92c
work_keys_str_mv	AT tialkauffman feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT yolandakprado feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT anaareyes feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT jamilynmzepp feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT jennifersawyer feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT larissaleewhite feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT jessicamartucci feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT suzannebiancasalas feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT sarahvertrees feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT alanfrope feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT sheilaweinmann feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT norabhenrikson feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT sandrasoojinlee feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT heatherspencerfeigelson feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol AT jessicaezzellhunter feasibilityofatracebackapproachforusingpathologyspecimenstofacilitategenetictestinginthegeneticriskanalysisinovariancancergracestudyprotocol
_version_	1718411588477648896

Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol

Ejemplares similares